Targeting tumour vasculature: The development of combretastatin A4

Lancet Oncology

Volumn 2, Issue 2, 2001, Pages 82-87

  Griggs, Jeremy ^a   Metcalfe, James C ^a   Hesketh, Robin ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN A 4; COMBRETASTATIN A-4; STILBENE DERIVATIVE;

CELL CULTURE; CLINICAL TRIAL; HUMAN; NEOPLASM; REVIEW; VASCULARIZATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELLS, CULTURED; CLINICAL TRIALS; HUMANS; NEOPLASMS; STILBENES;

EID: 0035262598     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00224-2     Document Type: Review

References (37)

1. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
2. Asahara T., Masuda M., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularisation. Circ Res. 85:1999;221-228.
3. Takahashi T., Kalka C., Masuda H., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial cell progenitor cells for neovascularisation. Nat Med. 5:1999;434-438.
4. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
5. Maeda K., Chung Y., Takatsuka S., et al. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol. 13:1995;477-481.
6. Inoue K., Ozeki Y., Suganuma T., et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer. 79:1997;206-213.
7. Volm M., Koomagi R., Mattern J. Prognostic value of vascular endothelial growth factor and its receptor flt-1 in squamous cell lung cancer. Int J Cancer. 74:1997;64-68.
8. Weidener N., Folkman J., Pozza F., et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst. 84:1993;1875-1887.
9. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist. 5:2000;20-27.
10. Boehm T., Folkman J., Browder T., Oreilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
11. Matsumura Y., Maeda H. A new concept for macro-molecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 6:1986;6387-6392.
12. Ludford R.J. Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst. 6:1945;89-101.
13. Pettit G.R., Toki B., Herald D.L., et al. Antineoplastic agents, 379: synthesis of phenstatin phosphate. J Med Chem. 41:1998;1688-1695.
14. Lin C.M., Ho H.H., Pettit G.R., Hamel E. Antimitotic natural-products combretastatin-A-4 and combretastatin-A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry. 28:1989;6984-6991.
15. Dark G.G., Hill S.A., Prise V.E., et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1997;1829-1834.
16. Ohsumi K., Nakagawa R., Fukuda Y., et al. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem. 41:1998;3022-3032.
17. Iyer S., Chaplin D.J., Rosenthal D.S., et al. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58:1998;4510-4514.
18. Grosios K., Holwell S.E., McGown A.T., et al. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer. 81:1999;1318-1327.
19. Galbraith S.M., Lee F., Vojnovic B., et al. Quantitative analysis of endothelial cell shape change after treatment with combretastatin A4 phosphate. Clin Cancer Res. 5:(SS):1999;399.
20. Kanthou C., Tozer G.M. Studies on the mechanism of action of the vascular targeting agent combretastatin A4-phosphate. Br J Cancer. 83:(S1):2000;12.
21. Chaplin D.J., Pettit G.R., Hill S.A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 19:1999;189-195.
22. Grosios K., Loadman P.M., Swaine D.J., et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 20:2000;229-233.
23. Galbraith S., Tozer G.M., Dark G., Chaplin D.J. Tumour neovasculature as a target for drug therapy: studies with combretastatin A4 phosphate. Br J Cancer. 80:(S2):1999;91.
24. Horsman M.R., Ehrnrooth E., Ladekarl M., Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys. 42:1998;895-898.
25. Hori K., Saito S., Nihei Y., et al. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res. 90:1999;1026-1038.
26. Beauregard D.A., Thelwall P.E., Chaplin D.J., et al. Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer. 77:1998;1761-1767.
27. Zhao S., Moore J.V., Waller M.L., et al. Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. Eur J Nucl Med. 26:1999;231-238.
28. Tozer G.M., Prise V.E., Wilson J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 59:1999;1626-1634.
29. Li L.Y., Rojiani A., Siemann D.W. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys. 42:1998;899-903.
30. Stratford M, Folkes L, Galbraith S, et al. Phase I pharmacokinetic and toxicity study of weekly intravenous combretastatin A4 phosphate (CA4P). NCI/AACR/EORTC symposium on New Drugs in Cancer Therapy, Amsterdam 2000.
31. Stevenson JP, Gallagher M, Sun W, et al. Phase I/pharmocokinetic trial of the endothelial toxin combretastatin A4P (CA4P) administered as an IV bolus on a daily x 5 schedule every 21 days. Proceedings of the 91st Annual Meeting of the American Association of Cancer Research 2000: 3469.
32. Remick SC, Dowlati A, Lewin J, et al. A Phase I pharmacokinetic(PK) study of single dose intravenous (IV) combretastatin A4prodrug (CA4P) in patients (PTS) with advanced cancer. Program of Proceedings, American Society of Clinical Oncologists 2000: 697.
33. Anderson H, Jap J, Price P. Measurement of tumour andnormal (NT) perfusion by positron emission tomography(PET) in the evaluation of antivascular therapy: results inthe phase I study of combretastatin A4 phosphate (CA4P).Program Proceedings, American Society of Clinical Oncologists2000: 695.
34. Galbraith S.M., Taylor N.J., Maxwell R.J., et al. Combretastatin A4 phosphate (CA4P) targets vasculature in animal and human tumours. Br J Cancer. 83:(suppl 1):2000;12.
35. Folberg R., Hendrix M.J., Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 156:2000;361-381.
36. McDonald D.M., Munn L., Jain R.K. Vasculogenic mimicry: how convincing, how novel, and how significant? Am J Pathol. 156:2000;383-388.
37. Eikesdal H.P., Schem B.C., Mella O., Dahl O. The newtubulin-inhibitor combretastatin A-4 enhances thermaldamage in the BT(4)An rat glioma. Int J Radiat Oncol Biol Phys. 46:2000;645-652.